相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Functional genomic landscape of acute myeloid leukaemia
Jeffrey W. Tyner et al.
NATURE (2018)
E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia
I-K Park et al.
LEUKEMIA (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis
Catherine C. Smith et al.
BLOOD (2017)
Leukemogenic potency of the novel FLT3-N676K mutant
Kezhi Huang et al.
ANNALS OF HEMATOLOGY (2016)
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
Klaus H. Metzeler et al.
BLOOD (2016)
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Elie Traer et al.
CANCER RESEARCH (2016)
Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse
Jason E. Farrar et al.
CANCER RESEARCH (2016)
Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients
Svetlana A. Smirnikhina et al.
LEUKEMIA & LYMPHOMA (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Secondary mutations as mediators of resistance to targeted therapy in leukemia
Naval Daver et al.
BLOOD (2015)
Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse
Manoj Garg et al.
BLOOD (2015)
Mutational Cooperativity Linked to Combinatorial Epigenetic Gain of Function in Acute Myeloid Leukemia
Alan H. Shih et al.
CANCER CELL (2015)
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
C. C. Smith et al.
LEUKEMIA (2015)
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 Gatekeeper F691L Mutation with PLX3397
Catherine C. Smith et al.
CANCER DISCOVERY (2015)
Analysis of drug combinations: current methodological landscape
Julie Foucquier et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Allison Galanis et al.
BLOOD (2014)
Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition
Julie Irving et al.
BLOOD (2014)
Treatment With FLT3 Inhibitor in Patients With FLT3-Mutated Acute Myeloid Leukemia Is Associated With Development of Secondary FLT3-Tyrosine Kinase Domain Mutations
Yesid Alvarado et al.
CANCER (2014)
Improved vectors and genome-wide libraries for CRISPR screening
Neville E. Sanjana et al.
NATURE METHODS (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Crenolanib is a selective type I pan-FLT3 inhibitor
Catherine Choy Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
Seth A. Wander et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia
Eric I. Zimmerman et al.
BLOOD (2013)
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
Catherine C. Smith et al.
BLOOD (2013)
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Farhad Ravandi et al.
BLOOD (2013)
Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia
Sharyn D. Baker et al.
CLINICAL CANCER RESEARCH (2013)
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
C. Albers et al.
LEUKEMIA (2013)
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Kristian Cibulskis et al.
NATURE BIOTECHNOLOGY (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and c-Met Inhibitor Resistance in Non-Small Cell Lung Cancer
Jason T. Fong et al.
PLOS ONE (2013)
Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
Cheuk Him Man et al.
BLOOD (2012)
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
Daniel C. Koboldt et al.
GENOME RESEARCH (2012)
Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis
Salut Brunet et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
A. S. Moore et al.
LEUKEMIA (2012)
Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML
Wei Li et al.
LEUKEMIA RESEARCH (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12
Kensuke Kojima et al.
BLOOD (2011)
Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor
William McLaren et al.
BIOINFORMATICS (2010)
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
Aaron McKenna et al.
GENOME RESEARCH (2010)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Prognostic relevance of FLT3-TKD mutations in AML:: the combination matters -: an analysis of 3082 patients
Ulrike Bacher et al.
BLOOD (2008)
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Stefan Froehling et al.
CANCER CELL (2007)
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways
Obdulio Piloto et al.
BLOOD (2007)
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
F Heidel et al.
BLOOD (2006)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm
S Fröhling et al.
BLOOD (2002)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
分享论文
